T1	CHEM 57 69	ceralasertib
T2	CHEM 74 84	durvalumab
#1	AnnotatorNotes T2	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 94 103	docetaxel
#2	AnnotatorNotes T3	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T4	LIVB 107 116	pacientes
#3	AnnotatorNotes T4	C0030705; Patients; Patient or Disabled Group
T5	DISO 121 152	cáncer de pulmón no microcítico
#4	AnnotatorNotes T5	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T6	Neg_cue 138 140	no
T7	Negated 141 152	microcítico
T8	DISO 164 175	metastásico
#5	AnnotatorNotes T8	C4255448; Metastasis; Pathologic Function
T9	PROC 198 256	Estudio de fase III, abierto, aleatorizado y multicéntrico
T10	CHEM 261 273	ceralasertib
T11	CHEM 278 288	durvalumab
#6	AnnotatorNotes T11	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T12	CHEM 298 307	docetaxel
#7	AnnotatorNotes T12	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T13	LIVB 311 320	pacientes
#8	AnnotatorNotes T13	C0030705; Patients; Patient or Disabled Group
T14	DISO 325 356	cáncer de pulmón no microcítico
#9	AnnotatorNotes T14	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T15	Neg_cue 342 344	no
T16	Negated 345 356	microcítico
T17	DISO 368 379	metastásico
#10	AnnotatorNotes T17	C4255448; Metastasis; Pathologic Function
T18	Neg_cue 380 383	sin
T19	DISO 384 406	alteraciones genómicas
T20	Negated 384 406	alteraciones genómicas
T21	DISO 445 455	enfermedad
#11	AnnotatorNotes T21	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T22	PROC 494 505	tratamiento
#12	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	CHEM 517 529	anti-PD-(L)1
T24	PROC 532 545	quimioterapia
#13	AnnotatorNotes T24	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure | C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T25	CHEM 559 566	platino
#14	AnnotatorNotes T25	C0032207; platinum; Element, Ion, or Isotope
T26	DISO 598 614	Cáncer de pulmón
#15	AnnotatorNotes T26	C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
T27	DISO 641 672	Cáncer de pulmón no microcítico
#16	AnnotatorNotes T27	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T28	Neg_cue 658 660	no
T29	Negated 661 672	microcítico
T30	DISO 684 695	metastásico
#17	AnnotatorNotes T30	C4255448; Metastasis; Pathologic Function
T31	LIVB 725 737	Participante
T32	Age 747 758	>/= 18 años
T33	DISO 794 825	Cáncer de pulmón no microcítico
#18	AnnotatorNotes T33	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T34	Neg_cue 811 813	no
T35	Negated 814 825	microcítico
T36	DISO 827 853	non-small cell lung cancer
T37	DISO 855 860	NSCLC
#19	AnnotatorNotes T37	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T38	PROC 875 904	histológica o citológicamente
T39	DISO 928 939	metastásico
#20	AnnotatorNotes T39	C4255448; Metastasis; Pathologic Function
T40	PROC 959 973	Estadificación
T41	DISO 1124 1151	Progresión de la enfermedad
#21	AnnotatorNotes T41	C0242656; Disease Progression; Pathologic Function
T42	DISO 1168 1175	disease
T43	DISO 1177 1179	PD
T44	PROC 1237 1259	régimen de tratamiento
T45	Date 1264 1272	reciente
T46	PROC 1292 1330	tratamiento de segunda o tercera línea
T47	PROC 1348 1372	tratamiento anti-PD-(L)1
T48	PROC 1375 1390	biquimioterapia
T49	CHEM 1395 1416	derivados del platino
T50	DISO 1422 1427	NSCLC
#22	AnnotatorNotes T50	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T51	DISO 1450 1461	metastásico
#23	AnnotatorNotes T51	C4255448; Metastasis; Pathologic Function
T52	PROC 1505 1521	Estado funcional
T53	PHYS 1548 1561	Funcionalidad
T54	ANAT 1581 1588	medular
#24	AnnotatorNotes T54	C0037925; Spinal Cord; Body Part, Organ, or Organ Component | C0376152; Marrow; Body Part, Organ, or Organ Component | C1550278; Medullary - body parts; Body Part, Organ, or Organ Component
T55	Duration 1630 1640	12 semanas
T56	PROC 1646 1659	Peso corporal
T57	Neg_cue 1670 1673	sin
T58	DISO 1674 1693	caquexia neoplásica
T59	Negated 1674 1693	caquexia neoplásica
T60	PROC 1699 1717	Prueba de embarazo
#25	AnnotatorNotes T60	C0032976; Pregnancy Tests; Diagnostic Procedure
T61	Negated 1709 1717	embarazo
T62	Neg_cue 1718 1726	negativa
T63	ANAT 1731 1736	suero
#26	AnnotatorNotes T63	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T64	LIVB 1745 1776	mujeres potencialmente fértiles
T65	Spec_cue 1753 1767	potencialmente
T66	Speculated 1768 1776	fértiles
T67	LIVB 1807 1819	Participante
T68	PROC 1824 1840	histología mixta
T69	DISO 1844 1891	carcinoma pulmonar microcítico y no microcítico
T70	Neg_cue 1877 1879	no
T71	Negated 1880 1891	microcítico
T72	DISO 1917 1943	neoplasia maligna primaria
#27	AnnotatorNotes T72	C1306459; Primary malignant neoplasm; Neoplastic Process
T73	Neg_cue 1945 1952	excepto
T74	PROC 1967 1974	tratada
T75	Negated 1967 1974	tratada
T76	Neg_cue 2000 2002	no
T77	Negated 2017 2043	actividad de la enfermedad
T78	DISO 2033 2043	enfermedad
#28	AnnotatorNotes T78	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T79	Duration 2044 2054	>/= 5 años
T80	PROC 2085 2096	tratamiento
#29	AnnotatorNotes T80	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T81	DISO 2113 2128	Efectos tóxicos
#30	AnnotatorNotes T81	C0600688; Toxic effect; Injury or Poisoning
T82	PROC 2174 2200	tratamiento antineoplásico
T83	DISO 2212 2255	Trastornos autoinmunitarios o inflamatorios
T84	LIVB 2291 2304	Participantes
T85	CHEM 2344 2356	anti-PD-(L)1
T86	LIVB 2402 2415	participantes
T87	Neg_cue 2421 2423	No
T88	DISO 2447 2456	toxicidad
#31	AnnotatorNotes T88	C0600688; Toxic effect; Injury or Poisoning
T89	Negated 2447 2456	toxicidad
T90	PROC 2476 2525	suspensión permanente del tratamiento anti-PD(L)1
T91	DISO 2585 2609	acontecimientos adversos
#32	AnnotatorNotes T91	C0877248; Adverse event; Pathologic Function
T92	DISO 2611 2618	adverse
T93	DISO 2627 2629	AE
T94	PROC 2652 2675	tratamiento anti-PD(L)1
T95	Neg_cue 2689 2691	No
T96	Negated 2715 2739	AE de origen inmunitario
T97	DISO 2715 2717	AE
T98	ANAT 2728 2739	inmunitario
T99	Negated 2741 2771	immune-mediated adverse events
T100	Neg_cue 2794 2796	ni
T101	DISO 2797 2843	AE neurológicos u oculares de tipo inmunitario
T102	Negated 2797 2843	AE neurológicos u oculares de tipo inmunitario
T103	Neg_cue 2847 2853	ningún
T104	Negated 2854 2859	grado
T105	PROC 2871 2894	tratamiento anti-PD(L)1
T106	Neg_cue 2907 2909	No
T107	PROC 2932 2947	inmunosupresión
#33	AnnotatorNotes T107	C0021079; Therapeutic immunosuppression; Therapeutic or Preventive Procedure
T108	Negated 2932 2947	inmunosupresión
T109	CHEM 2970 2986	corticosteroides
#34	AnnotatorNotes T109	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T110	Negated 2970 2986	corticosteroides
T111	PROC 2995 3006	tratamiento
#35	AnnotatorNotes T111	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T112	DISO 3013 3015	AE
T113	Neg_cue 3017 3019	no
T114	Negated 3043 3063	reaparición de un AE
T115	DISO 3043 3054	reaparición
T116	DISO 3061 3063	AE
T117	Neg_cue 3090 3092	no
T118	Date 3108 3124	en la actualidad
T119	Negated 3125 3169	dosis de mantenimiento > 10 mg de prednisona
T120	Dose 3125 3155	dosis de mantenimiento > 10 mg
T121	CHEM 3159 3169	prednisona
#36	AnnotatorNotes T121	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T122	Frequency 3184 3190	al día
T123	LIVB 3195 3208	Participantes
T124	PROC 3255 3268	quimioterapia
#37	AnnotatorNotes T124	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure | C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T125	CHEM 3273 3294	derivados del platino
T126	DISO 3300 3322	enfermedad metastásica
#38	AnnotatorNotes T126	C0341683; Hydatid cyst of kidney; Disease or Syndrome
T127	LIVB 3327 3340	Participantes
T128	CHEM 3363 3379	inhibidor de ATR
